Iovance Biotherapeutics, Inc. (IOVA) Stock Price & How to Invest

Iovance Biotherapeutics (Nasdaq: IOVA) develops tumor-infiltrating lymphocyte (TIL) cell therapies, individualized treatments made from a patient's own immune cells. Its lead product, Amtagvi (lifileucel), became the first FDA-approved one-time T-cell therapy for a solid tumor when it was cleared for advanced melanoma, and the company also sells Proleukin, an interleukin-2 product used alongside TIL treatment. Iovance manufactures Amtagvi in-house at its Iovance Cell Therapy Center and has treated more than 1,500 patients across commercial and clinical use, with regulatory approvals in the US, Canada and Australia and decisions in the UK, Switzerland and Europe still pending.

The investment picture is a classic early-commercial biotech: revenue is growing quickly off a small base while the company is still losing money. Full-year 2025 product revenue was roughly $264 million. Second-quarter 2026 revenue reached about $99 million, up about 66% from a year earlier (roughly $91 million from Amtagvi and $9 million from Proleukin), and the net loss narrowed to about $47 million, with a loss of $0.11 a share against a $0.13 estimate. On September 29, 2026 Iovance raised its 2026 revenue guidance to $410 million to $420 million from $350 million to $370 million, citing strong US demand for Amtagvi and Proleukin, and the shares jumped about 35% that day. As of October 16, 2026 IOVA closed near $13.81, up about 448% year to date and 517% over one year, for a market capitalization near $6.3 billion, or roughly 19 times trailing revenue. The stock now reflects expectations that the ramp continues, manufacturing scale lifts margins, and pipeline programs in lung cancer, endometrial cancer, and other tumors eventually broaden the franchise. The bull case rests on execution; the bear case is dilution, competition, and the operational complexity of individualized cell therapy. Third-quarter results are scheduled for November 5, 2026, with consensus near $115 million of revenue.

Iovance remains unprofitable and has historically funded operations with stock sales, so ongoing dilution is a real risk to existing shareholders. Amtagvi is a complex, individualized therapy that requires surgery, lymphodepletion, and specialized centers, which can slow adoption and limit the eligible patient pool. Competition from other cell therapies and immuno-oncology approaches, including engineered TIL and CAR-T efforts, could pressure the franchise over time. Manufacturing disruptions, reimbursement hurdles, or clinical setbacks in pipeline programs would materially hurt the growth thesis. The shares are highly volatile and sensitive to guidance changes and trial data: after rising about 448% in 2026 to a value near 19 times trailing revenue, the stock now prices in sustained growth, so a soft quarter or delayed approval in Europe could reverse a large part of the move. Trailing operating cash burn was still about $264 million.

10 analysts publish price targets on IOVA, averaging $14.40 against a $13.62 price as of October 2026, or +5.7%. The published targets run from $7.00 to $20.00, a wide spread, and the ratings split 8 buy, 2 hold, 0 sell. Over the last six months there have been 10 raises and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full IOVA forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Iovance Biotherapeutics, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Amtagvi commercial ramp. Amtagvi is the core growth engine, with U.S. The most optimistic published target, $20.00, assumes this works close to its best case.

The case against. Iovance remains unprofitable and has historically funded operations with stock sales, so ongoing dilution is a real risk to existing shareholders. The most pessimistic target, $7.00, is roughly what IOVA is worth if this bites instead.

Read the full bull and bear case on IOVA, including what would have to change to break either one. Walnut is not an investment adviser.

No. Iovance Biotherapeutics, Inc. (IOVA) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Iovance Biotherapeutics, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$325M; Q2 2026 ~$99M, up ~66% year over year
• FY2026 revenue guidance: ~$410M to $420M (raised Sept 29 from $350M to $370M)
• Gross margin (TTM): ~48%; operating margin ~-52%
• Net loss: ~$290M TTM; Q2 2026 ~$47M (EPS -$0.11 vs -$0.13 est.)
• Market cap: ~$6.3B at ~$13.81 per share (Oct 16, 2026)
• Valuation: No P/E (loss-making); ~19x trailing sales
• Cash (June 30, 2026): ~$298M; debt ~$46M

Iovance now trades at roughly 19 times trailing revenue, up from about five times in mid-2026, a multiple that reflects rapid growth expectations rather than current earnings, since the company is still posting net losses. Losses have been narrowing as Amtagvi revenue scales and margins improve, and analysts expect revenue near $413 million in 2026 and $594 million in 2027. The 10 analysts tracked have a mean target of about $14.40, close to the current price after the rally, so valuation hinges on whether the ramp keeps beating the raised guidance.

If you want IOVA exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

Other names that sit close to IOVA: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get IOVA exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (XBI), which spreads the position across many companies. Or build it into a focused thematic portfolio, so IOVA sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where IOVA fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

IOVA is an execution-driven biotech bet on Amtagvi's ramp and pipeline. After a roughly fivefold rise in 2026 and a market value near $6.3 billion, it is priced for continued fast growth while the company is still losing money, which raises the bar for every quarter.

Whether IOVA is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is IOVA a buy or a sell?, and where the stock could go from here in the IOVA stock forecast.

For income investors, whether IOVA pays a dividend and how the payout looks is covered in does IOVA pay a dividend? And to weigh IOVA against a peer, read the full side-by-side comparisons: IOVA vs BMY and IOVA vs CAR.